According to Stryker Corporation's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 39.8993. At the end of 2021 the company had a P/E ratio of 50.6.
Year | P/E ratio | Change |
---|---|---|
2021 | 50.6 | -11.91% |
2020 | 57.4 | 52.25% |
2019 | 37.7 | 128.19% |
2018 | 16.5 | -70.88% |
2017 | 56.7 | 108.77% |
2016 | 27.2 | 11.66% |
2015 | 24.3 | -58.99% |
2014 | 59.3 | 109.23% |
2013 | 28.4 | 76.38% |
2012 | 16.1 |
Company | P/E ratio | P/E ratio differencediff. | Country |
---|---|---|---|
![]() Medtronic MDT | 29.5 | -26.04% | ๐ฎ๐ช Ireland |
![]() Baxter BAX | -6.66 | -116.69% | ๐บ๐ธ USA |
![]() Boston Scientific BSX | 89.3 | 123.90% | ๐บ๐ธ USA |
![]() Edwards Lifesciences EW | 30.7 | -23.09% | ๐บ๐ธ USA |
![]() Waters Corporation WAT | 23.6 | -40.81% | ๐บ๐ธ USA |
![]() Integra LifeSciences IART | 24.4 | -38.83% | ๐บ๐ธ USA |
![]() Smith & Nephew
SNN | 22.6 | -43.35% | ๐ฌ๐ง UK |
![]() Owens & Minor
OMI | -12.1 | -130.31% | ๐บ๐ธ USA |
![]() Hill-Rom HRC | N/A | N/A | ๐บ๐ธ USA |
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.